Insight Molecular Diagnostics Inc. (ticker: IMDX) is an NASDAQ-listed in vitro & in vivo diagnostic substances company. DredgeCap's structured extraction of IMDX's SEC filings surfaces 5 active risk signals, including 2 auditor-change signals, 2 late-filing signals, and 1 delisting/deregistration signal. IMDX reported $32K in revenue and -$4.29M for the period ending 2026-03-31, with operating cash flow of -$7.64M. Cash and equivalents stood at $28.20M (down 9.1% year-over-year). Total assets of $40.43M are exceeded by total liabilities of $51.12M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.
IMDX Legal Proceedings
DredgeCap has not located any disclosed legal proceedings for Insight Molecular Diagnostics Inc. (IMDX) in the SEC filings currently cached or in the federal-court records searched. 0 periodic filings reviewed, 0 with specific disclosure content. The absence of records here does not certify that the company is free of litigation — coverage reflects only what DredgeCap has cached.